Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Atea Pharmaceuticals (AVIR) Strong Sell-Off 'Premature' - William Blair
October 19, 2021 10:55 AM EDTWilliam Blair analyst Tim Lugo reiterated an Outperform rating and {REMOVEPT} price target on Atea Pharmaceuticals (NASDAQ: AVIR) amid today's sell-off, calling it "premature."
The analyst commented, "While the top-line miss in the Phase II MOONSONG study is a setback for Atea, we... More
Atea Pharmaceuticals Inc. (AVIR) to Resume Trading at 7:30 a.m.
October 19, 2021 7:10 AM EDTAtea Pharmaceuticals Inc. (NASDAQ: AVIR) to Resume Trading at 7:30 a.m.
... MoreMerck (MRK) Strength Pre-Open Tied to Atea Pharmaceuticals Inc. (AVIR) Trial Missing Primary Endpoint
October 19, 2021 7:09 AM EDTMerck (NYSE: MRK) Strength Pre-Open Tied to Atea Pharmaceuticals Inc. (NASDAQ: AVIR) Trial Missing Primary Endpoint
Merck up 2.2%, Atea Still Halted... More